Výsledky vyhledávání

Sequential combination chemotherapy in human breast cancer: a basis for increased antineoplastic activity and bone marrow protection

Autor: J H, Davis, J A, Desoto, E B, Fryar, W M, Southerland, D, Bowen

Publikováno v: Cellular and molecular biology (Noisy-le-Grand, France). 53(3)

These studies were designed to develop procedures that would capitalize on the growth inhibitory effects of tamoxifen (Tam) and methotrexate (MTX) in breast cancer, while protecting bone marrow with a priming dose of 5-fluorouracil (5-FU). High-dose

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f85d72f18b04e5c4141295c4088ba9fa
https://pubmed.ncbi.nlm.nih.gov/17531145

Zobrazit plný text záznamu

The interaction of the steroidal antagonist faslodex and methotrexate

Autor: J A, DeSoto, D, Bowen, W M, Southerland, M, Hawkins, E B, Fryar, J H, Davis

Publikováno v: Cellular and molecular biology (Noisy-le-Grand, France). 49(7)

Faslodex (FAS, ICI 182, 780), a novel steroidal estrogen antagonist decreased high-dose methotrexate (MTX) cytotoxicity in MCF-7 breast cancer cells. When FAS is given at least 24 hr prior to MTX, the resultant interaction is antagonistic. However, w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::19dc2c9ff9c12f33212f3df1346e6b0a
https://pubmed.ncbi.nlm.nih.gov/14682388

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání